Management of Splenic Vein Thrombosis in Acute Pancreatitis

Diagnostic Approach

Imaging with CT with IV contrast, MRI, or endoscopic ultrasound (EUS) is essential for diagnosis and assessment of extent of thrombosis in patients with acute pancreatitis, according to the National Comprehensive Cancer Network 1, 2
Laboratory markers including lipase, amylase, white blood cell count, C-reactive protein, and procalcitonin should be monitored in patients with suspected splenic vein thrombosis 1
Determine if thrombosis is acute (symptoms ≤8 weeks, no cavernous transformation/collaterals, no portal hypertension) or chronic (symptoms >8 weeks, presence of cavernous transformation/collaterals, signs of portal hypertension) in patients with splenic vein thrombosis 2

Anticoagulation therapy is recommended for symptomatic cases to reduce morbidity and mortality in patients with splenic vein thrombosis, as suggested by the National Comprehensive Cancer Network 3
Low-molecular-weight heparin (LMWH) at therapeutic doses should be initiated as first-line therapy for symptomatic splenic vein thrombosis, according to the National Comprehensive Cancer Network 2, 4
A minimum duration of 3 months of anticoagulation is recommended for patients with symptomatic splenic vein thrombosis 3

Screen for gastrointestinal varices before initiating anticoagulation as they are predictors of bleeding risk in patients with splenic vein thrombosis, as recommended by Praxis Medical Insights 3, 4
Assess for signs of intestinal infarction (severe abdominal pain, rectal bleeding) which requires urgent surgical intervention in patients with splenic vein thrombosis, according to the National Comprehensive Cancer Network 2
Consider local consultation with radiology to optimize imaging techniques for incidental splanchnic vein thrombosis in patients with acute pancreatitis, as suggested by the National Comprehensive Cancer Network 2

Perform cross-sectional imaging every 3 months to assess response to treatment in patients with splenic vein thrombosis, as recommended by Praxis Medical Insights 4
Recanalization can be expected to occur up to 6 months after starting treatment in patients with splenic vein thrombosis, according to Praxis Medical Insights 4
Time interval between diagnosis and start of anticoagulation less than 6 months is the most important factor predicting successful recanalization in patients with splenic vein thrombosis, as suggested by Praxis Medical Insights 4

LMWH is the preferred initial treatment for patients with splenic vein thrombosis, according to the National Comprehensive Cancer Network 2, 4
For patients without cirrhosis, options include LMWH, vitamin K antagonists (VKA), or direct oral anticoagulants (DOACs) for the treatment of splenic vein thrombosis, as recommended by Praxis Medical Insights 4
Monitor anti-Xa activity in overweight patients, pregnant patients, and those with poor kidney function receiving LMWH for splenic vein thrombosis, as suggested by Praxis Medical Insights 4

For chronic splenic vein thrombosis with signs of portal hypertension, consider beta blockers, variceal banding or sclerosis, according to the National Comprehensive Cancer Network 2
In cases of intestinal infarction, immediate surgical evaluation is required to resect necrotic sections of the bowel, as recommended by the National Comprehensive Cancer Network 2
For patients with progressive thrombosis not responding to anticoagulation, consider transjugular intrahepatic portosystemic shunt (TIPS), as suggested by Praxis Medical Insights 4